Integra LifeSciences came into this earnings print with a bruised share price over the past month, yet the stock jumped 3.8% to US$17.12 after the release. The market is reacting to one thing above all else: margin repair finally showed up in the numbers.

Adjusted earnings per share of US$0.56 and an adjusted EBITDA margin of 18.7% put profit quality back at the center of the Integra LifeSciences story. For a company still working through past setbacks, this quarter is less about sales volume and more about proof that the profit engine can still run.

Love Integra LifeSciences Holdings' margin repair but want more stocks pairing solid profitability with balance sheet strength? Check out the list of solid balance sheet and fundamentals stocks (46 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$418.8 million vs. US$415.6 million (up 0.8%)
• Net Income (Q2 2026 vs. Q2 2025): US$4.5 million profit vs. US$484.1 million loss (returned to profit)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.06 per share vs. a loss of US$6.31 per share (returned to positive EPS)
• Adjusted EBITDA Margin (Q2 2026 vs. Q2 2025): 18.7% vs. 17.1% (up 1.6 percentage points, indicating margin repair at Integra LifeSciences)

Prefer clear visuals instead of long earnings transcripts and pages of raw figures? See Integra LifeSciences Holdings' full financial picture, with a focus on its valuation, in an easy to scan visual dashboard in the company report for Integra LifeSciences Holdings.

Integra margin story hits key proof points

Bulls argue that Integra LifeSciences can turn years of remediation work into a cleaner, higher margin business. This quarter gives some concrete support to that view. Adjusted EBITDA margin moved to 18.7%, up from 17.1%, while gross margin improved 60 bps to 61.3%. That aligns with management’s targeted US$25m to US$30m cost savings in 2026 and early traction from the transformation program.

Execution is not just about cost. Specialty Surgery delivered 1.6% organic growth with neurosurgery products such as Certas Plus, CUSA and Bactiseal benefiting from better supply reliability. PriMatrix has recovered to more than 50% of pre recall revenue roughly nine months after relaunch, which supports the thesis that Integra can recapture at least part of lost wound care share once products return. Reaffirmed full year EPS guidance of US$2.40 to US$2.50 also fits the margin repair narrative.

Bear risks on growth mix and leverage persist

Bears focus on sluggish growth, high leverage and regulatory overhang. Q2 results do not fully clear those concerns. Organic revenue growth was 0.7%, which keeps Integra LifeSciences close to the 2% to 3% average that previously worried investors. Tissue Reconstruction, central to the wound care story, declined about 2% organically, and ENT remains under pressure from reimbursement and is expected to be down for the year.

Leverage is lower at 4.1x total, but net debt is still about US$1.6b, and management flagged higher interest expense in the second half tied to refinancing. That tempers the benefit from tariff tailwinds and cost savings. Regulatory and product relaunch milestones are also still ahead. SurgiMend and MediHoney are not expected to contribute meaningfully until 2027 and quality warning letter tasks are only targeted for completion by the end of 2026.

After a period of volatile trading and questions around interest coverage, you may want to review whether these are isolated issues. Expose Integra LifeSciences Holdings' full risk profile in the risk analysis for Integra LifeSciences Holdings which shows 2 important warning signs.

Guide Your Next Investment Move

If Integra LifeSciences Holdings' margin repair story has your attention but you are still weighing the growth and leverage trade off, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the thesis develops. Once you own any stock, use the Portfolio Command Center to cut through market noise and stay focused on the updates that actually affect your holdings. For a broader perspective on Integra LifeSciences and peers, turn to the Community to see how other investors are interpreting the same data. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Integra LifeSciences?

Fresh ideas can move fast. New themes gain momentum, early prices start flying, and latecomers get caught chasing. Scan these curated stock sets before the edge drops and consider acting while opportunities are still developing.

• Spot companies quietly building momentum in critical infrastructure and grid upgrades by reviewing the curated 35 power grid technology and infrastructure stocks while they are still under the radar for now.
• Zero in on businesses transforming factories and logistics, then use the focused 34 robotics and automation stocks to find stocks where automation demand could become a powerful breakout story.
• Track the expanding backbone of AI data centers and hardware acceleration by checking the targeted 56 AI infrastructure stocks while the market is still assessing that growth potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.